Stay informed with the latest updates for the inheritable blood disorders community.

Industry
Octapharma Announces Final Results of Nuwiq® Study
NBDF & Community
This national survey is designed to assess patient demographics, their satisfaction with the HTC’s core treatment team, its services, and care processes.
Third National Patient Satisfaction Survey Launching Soon!
NBDF & Community
NHF Wednesday Webinars 2021
Wednesday Webinar February 2021 Speakers
Advocacy & Legislative
The special enrollment period lasts from February 15th to May 15th, 2021.
ACA Marketplaces to Reopen
Industry
The phase 3 trial currently includes 134 participants with hemophilia A, all of whom have received a single dose of the gene therapy.
BioMarin Announces Positive Phase 3 Study Data for Valoctocogene…
NBDF & Community
Ampoule bottle assembly line banner
Recall Notice: Voluntary Recall Mononine Coagulation Factor IX (Human)
Medical
Medscape Activity Designed to Prepare Clinicians for Arrival of Gene…
Medical
These guidelines are an important step in our quest to address the difficulties individuals go through to obtain an accurate, timely diagnosis, and appropriate treatment.
New Guidelines on the Diagnosis and Management of VWD
NBDF & Community
JML Fellowship Launches
New Research Fellowship Available from NHF
NBDF & Community
Looking Ahead to 2021
NBDF & Community
Letter to the NHF Community
A Message from NHF President and CEO Leonard A. Valentino, MD
COVID-19
COVID-19 Vaccination Guidance from NHF, WFH, EAHAD, and…
Advocacy & Legislative
Washington D.C. - Capitol Building
NHF Applauds Congressional Enactment of The Hemophilia SNF Access Act
Industry
FDA Puts Clinical Hold on uniQure's Hope B Trial
FDA Puts Clinical Hold on uniQure's Hope B Trial
NBDF & Community
Boardroom
NHF Announces Three New Board Members